PressJuly 16, 2026 Eli Lilly to acquire AtaiBeckley for about $2.8 billion, up to $3.8 billion with milestones
PressJuly 16, 2026 Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
PressJuly 16, 2026 Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
PressJuly 16, 2026 Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
PressJuly 15, 2026 SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
PressJuly 14, 2026 FDA finalizes psychedelic clinical trial guidance and schedules September public hearing
PressJuly 14, 2026 Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
PressJuly 7, 2026 Compass Pathways reports six-month Phase 3 COMP006 data confirming durable psilocybin response
PressJuly 6, 2026 AtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression
PressJune 24, 2026 Helus Pharma reports APPROACH Phase 3 enrollment past 86% and launches $50M offering
PressJune 22, 2026 Definium's Phase 3 Emerge study of DT120 (LSD) meets primary endpoint in major depression
